|
Market Closed -
Nasdaq
23:00:00 28/08/2026 +03
|
5-day change | 1st Jan Change | ||
| 9.180 USD | -0.65% |
|
-1.98% | -22.60% |
| 08-10 | Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says | MT |
| 08-10 | Morgan Stanley Adjusts Price Target on Arvinas to $10 From $11, Maintains Equalweight Rating | MT |
Chart: Technical Analysis
Stock exchange
Nasdaq
ARVN 9.180 $
-0.65%
5.51M
$
| Markets | Price | Change | Volumes | ||
|---|---|---|---|---|---|
Nasdaq
| ARVN | 9.180USD | -0.65% | 5.51M $ | |
CBOE
| ARVN | 9.160USD | -0.84% | 251K $ |
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bullish | Bearish | Bearish |
| Resistance | 9.82 | 9.82 | 10.1 |
| Spread/Res. | -6.52% | -6.52% | -9.11% |
| Spread/Supp. | +3.49% | +31.52% | +23.72% |
| Support | 8.87 | 6.98 | 7.42 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- ARVN Stock
- Charts Arvinas, Inc.
Select your edition
All financial news and data tailored to specific country editions
